N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide
| Title | Journal |
|---|---|
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | The Biochemical journal 20130415 |
| In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. | Veterinary and comparative oncology 20120901 |
| Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. | Veterinary and comparative oncology 20120901 |
| Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. | European journal of haematology 20120701 |
| NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. | Allergy 20120701 |
| Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. | Veterinary and comparative oncology 20120601 |
| Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. | Investigational new drugs 20120401 |
| Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. | Molecular immunology 20120401 |
| Stevens-Johnson Syndrome induced by masitinib. | Acta dermato-venereologica 20120301 |
| Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. | Journal of veterinary pharmacology and therapeutics 20120201 |
| [KIT and KIT: from biology to clinical use]. | Bulletin du cancer 20120201 |
| Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. | Veterinary journal (London, England : 1997) 20120101 |
| The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. | International archives of allergy and immunology 20120101 |
| Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. | BMC neurology 20120101 |
| Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. | Veterinary dermatology 20111201 |
| Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. | Journal of surgical oncology 20111201 |
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | Nature biotechnology 20111101 |
| Comprehensive analysis of kinase inhibitor selectivity. | Nature biotechnology 20111030 |
| Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. | Seminars in oncology 20110401 |
| Stratified medicine in selecting biologics for the treatment of severe asthma. | Current opinion in allergy and clinical immunology 20110201 |
| Safety of masitinib mesylate in healthy cats. | Journal of veterinary internal medicine 20110101 |
| Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. | Alzheimer's research & therapy 20110101 |
| Emerging therapies for severe asthma. | BMC medicine 20110101 |
| F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors. | ISRN gastroenterology 20110101 |
| Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. | PloS one 20110101 |
| Mast cells as cellular sensors in inflammation and immunity. | Frontiers in immunology 20110101 |
| Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. | American journal of hematology 20101201 |
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | Chemistry & biology 20101124 |
| Clinical trial on the efficacy of masitinib in canine IBD. | The Veterinary record 20101106 |
| Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. | American journal of veterinary research 20101101 |
| Churg and Strauss vasculitis in the course of masitinib treatment: a first report. | Allergy 20100801 |
| Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. | Cancer chemotherapy and pharmacology 20100701 |
| [Focus on GIST management]. | Bulletin du cancer 20100601 |
| The complexity of the complicity of mast cells in cancer. | The international journal of biochemistry & cell biology 20100501 |
| Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). | European journal of cancer (Oxford, England : 1990) 20100501 |
| Masitinib for the treatment of canine atopic dermatitis: a pilot study. | Veterinary research communications 20100101 |
| Drug-induced minimal change nephropathy in a dog. | Journal of veterinary internal medicine 20100101 |
| Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. | Biologics : targets & therapy 20100101 |
| c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. | Arthritis research & therapy 20100101 |
| Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. | PloS one 20100101 |
| 'Masitinib' is safe and effective for the treatment of canine mast cell tumors. | Journal of veterinary internal medicine 20100101 |
| Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. | BMC cancer 20100101 |
| [New drugs for small animals in 2009]. | Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere 20100101 |
| Pharmacokinetics of masitinib in cats. | Veterinary research communications 20091201 |
| Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. | Allergy 20090801 |
| Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. | Arthritis research & therapy 20090101 |
| More about masitinib. | Arthritis research & therapy 20090101 |
| Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. | PloS one 20090101 |
| Clinically relevant advances in rheumatoid arthritis therapy. | F1000 medicine reports 20090101 |
| [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. | Bulletin du cancer 20080101 |
| Masitinib is safe and effective for the treatment of canine mast cell tumors. | Journal of veterinary internal medicine 20080101 |